nodes	percent_of_prediction	percent_of_DWPC	metapath
Deferoxamine—XDH—Carboplatin—bone cancer	0.379	0.412	CbGbCtD
Deferoxamine—XDH—Cisplatin—bone cancer	0.324	0.352	CbGbCtD
Deferoxamine—XDH—Doxorubicin—bone cancer	0.217	0.236	CbGbCtD
Deferoxamine—Renal tubular disorder—Cisplatin—bone cancer	0.00611	0.0765	CcSEcCtD
Deferoxamine—Blindness—Cisplatin—bone cancer	0.0016	0.02	CcSEcCtD
Deferoxamine—Optic neuritis—Cisplatin—bone cancer	0.00144	0.018	CcSEcCtD
Deferoxamine—Serum creatinine increased—Cisplatin—bone cancer	0.00144	0.018	CcSEcCtD
Deferoxamine—Retinal disorder—Methotrexate—bone cancer	0.00136	0.0171	CcSEcCtD
Deferoxamine—Infection—Carboplatin—bone cancer	0.00107	0.0134	CcSEcCtD
Deferoxamine—Lung infiltration—Methotrexate—bone cancer	0.00104	0.013	CcSEcCtD
Deferoxamine—Pain—Carboplatin—bone cancer	0.000922	0.0115	CcSEcCtD
Deferoxamine—Body temperature increased—Carboplatin—bone cancer	0.000852	0.0107	CcSEcCtD
Deferoxamine—Neuropathy—Cisplatin—bone cancer	0.000832	0.0104	CcSEcCtD
Deferoxamine—Blindness—Epirubicin—bone cancer	0.000822	0.0103	CcSEcCtD
Deferoxamine—Local reaction—Epirubicin—bone cancer	0.000822	0.0103	CcSEcCtD
Deferoxamine—Local reaction—Doxorubicin—bone cancer	0.000761	0.00953	CcSEcCtD
Deferoxamine—Blindness—Doxorubicin—bone cancer	0.000761	0.00953	CcSEcCtD
Deferoxamine—Aphasia—Methotrexate—bone cancer	0.00075	0.00939	CcSEcCtD
Deferoxamine—Transaminases increased—Epirubicin—bone cancer	0.000748	0.00937	CcSEcCtD
Deferoxamine—Serum creatinine increased—Epirubicin—bone cancer	0.00074	0.00927	CcSEcCtD
Deferoxamine—Optic neuritis—Epirubicin—bone cancer	0.00074	0.00927	CcSEcCtD
Deferoxamine—Liver disorder—Methotrexate—bone cancer	0.000713	0.00894	CcSEcCtD
Deferoxamine—Renal failure acute—Cisplatin—bone cancer	0.000697	0.00873	CcSEcCtD
Deferoxamine—Transaminases increased—Doxorubicin—bone cancer	0.000692	0.00867	CcSEcCtD
Deferoxamine—Cyanosis—Methotrexate—bone cancer	0.000687	0.00861	CcSEcCtD
Deferoxamine—Serum creatinine increased—Doxorubicin—bone cancer	0.000685	0.00858	CcSEcCtD
Deferoxamine—Optic neuritis—Doxorubicin—bone cancer	0.000685	0.00858	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Cisplatin—bone cancer	0.000665	0.00833	CcSEcCtD
Deferoxamine—Blood creatinine increased—Cisplatin—bone cancer	0.000603	0.00755	CcSEcCtD
Deferoxamine—Scotoma—Epirubicin—bone cancer	0.000599	0.00751	CcSEcCtD
Deferoxamine—Injection site pain—Epirubicin—bone cancer	0.000557	0.00698	CcSEcCtD
Deferoxamine—Scotoma—Doxorubicin—bone cancer	0.000554	0.00695	CcSEcCtD
Deferoxamine—Blood disorder—Epirubicin—bone cancer	0.000545	0.00683	CcSEcCtD
Deferoxamine—Bone disorder—Methotrexate—bone cancer	0.000538	0.00674	CcSEcCtD
Deferoxamine—Abdominal discomfort—Cisplatin—bone cancer	0.000533	0.00668	CcSEcCtD
Deferoxamine—Injection site pain—Doxorubicin—bone cancer	0.000516	0.00646	CcSEcCtD
Deferoxamine—Blood disorder—Doxorubicin—bone cancer	0.000504	0.00632	CcSEcCtD
Deferoxamine—Bone disorder—Epirubicin—bone cancer	0.000504	0.00631	CcSEcCtD
Deferoxamine—Renal failure—Cisplatin—bone cancer	0.000487	0.0061	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Cisplatin—bone cancer	0.000486	0.00609	CcSEcCtD
Deferoxamine—Bone pain—Epirubicin—bone cancer	0.000475	0.00595	CcSEcCtD
Deferoxamine—Bone disorder—Doxorubicin—bone cancer	0.000466	0.00584	CcSEcCtD
Deferoxamine—Bradycardia—Cisplatin—bone cancer	0.000453	0.00567	CcSEcCtD
Deferoxamine—Injection site reaction—Epirubicin—bone cancer	0.000452	0.00567	CcSEcCtD
Deferoxamine—Bone pain—Doxorubicin—bone cancer	0.00044	0.00551	CcSEcCtD
Deferoxamine—Urinary tract disorder—Cisplatin—bone cancer	0.000439	0.00551	CcSEcCtD
Deferoxamine—Connective tissue disorder—Cisplatin—bone cancer	0.000437	0.00548	CcSEcCtD
Deferoxamine—Urethral disorder—Cisplatin—bone cancer	0.000436	0.00546	CcSEcCtD
Deferoxamine—Visual impairment—Cisplatin—bone cancer	0.000429	0.00537	CcSEcCtD
Deferoxamine—Neuropathy—Epirubicin—bone cancer	0.000427	0.00535	CcSEcCtD
Deferoxamine—Injection site reaction—Doxorubicin—bone cancer	0.000419	0.00524	CcSEcCtD
Deferoxamine—Cramps of lower extremities—Epirubicin—bone cancer	0.000418	0.00524	CcSEcCtD
Deferoxamine—Eye disorder—Cisplatin—bone cancer	0.000416	0.00521	CcSEcCtD
Deferoxamine—Tinnitus—Cisplatin—bone cancer	0.000415	0.0052	CcSEcCtD
Deferoxamine—Immune system disorder—Cisplatin—bone cancer	0.000402	0.00504	CcSEcCtD
Deferoxamine—Mediastinal disorder—Cisplatin—bone cancer	0.000401	0.00502	CcSEcCtD
Deferoxamine—Arrhythmia—Cisplatin—bone cancer	0.000398	0.00498	CcSEcCtD
Deferoxamine—Neuropathy—Doxorubicin—bone cancer	0.000395	0.00495	CcSEcCtD
Deferoxamine—Erythema—Cisplatin—bone cancer	0.000387	0.00485	CcSEcCtD
Deferoxamine—Cramps of lower extremities—Doxorubicin—bone cancer	0.000387	0.00485	CcSEcCtD
Deferoxamine—Renal failure acute—Methotrexate—bone cancer	0.000382	0.00479	CcSEcCtD
Deferoxamine—Hepatic function abnormal—Epirubicin—bone cancer	0.000378	0.00473	CcSEcCtD
Deferoxamine—Visual disturbance—Methotrexate—bone cancer	0.000372	0.00467	CcSEcCtD
Deferoxamine—Muscle spasms—Cisplatin—bone cancer	0.000372	0.00467	CcSEcCtD
Deferoxamine—Vision blurred—Cisplatin—bone cancer	0.000365	0.00457	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Methotrexate—bone cancer	0.000365	0.00457	CcSEcCtD
Deferoxamine—Renal failure acute—Epirubicin—bone cancer	0.000358	0.00448	CcSEcCtD
Deferoxamine—Hepatic function abnormal—Doxorubicin—bone cancer	0.00035	0.00438	CcSEcCtD
Deferoxamine—Renal impairment—Epirubicin—bone cancer	0.000347	0.00435	CcSEcCtD
Deferoxamine—Leukopenia—Cisplatin—bone cancer	0.000347	0.00434	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Epirubicin—bone cancer	0.000341	0.00428	CcSEcCtD
Deferoxamine—Convulsion—Cisplatin—bone cancer	0.000336	0.0042	CcSEcCtD
Deferoxamine—Renal failure acute—Doxorubicin—bone cancer	0.000331	0.00415	CcSEcCtD
Deferoxamine—Myalgia—Cisplatin—bone cancer	0.00033	0.00413	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000328	0.0041	CcSEcCtD
Deferoxamine—Renal impairment—Doxorubicin—bone cancer	0.000321	0.00402	CcSEcCtD
Deferoxamine—Oedema—Cisplatin—bone cancer	0.000316	0.00396	CcSEcCtD
Deferoxamine—Anaphylactic shock—Cisplatin—bone cancer	0.000316	0.00396	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Doxorubicin—bone cancer	0.000316	0.00396	CcSEcCtD
Deferoxamine—Infection—Cisplatin—bone cancer	0.000314	0.00393	CcSEcCtD
Deferoxamine—Nervous system disorder—Cisplatin—bone cancer	0.00031	0.00388	CcSEcCtD
Deferoxamine—Thrombocytopenia—Cisplatin—bone cancer	0.00031	0.00388	CcSEcCtD
Deferoxamine—Blood creatinine increased—Epirubicin—bone cancer	0.000309	0.00388	CcSEcCtD
Deferoxamine—Tachycardia—Cisplatin—bone cancer	0.000309	0.00387	CcSEcCtD
Deferoxamine—Skin disorder—Cisplatin—bone cancer	0.000307	0.00385	CcSEcCtD
Deferoxamine—Asthma—Methotrexate—bone cancer	0.000305	0.00382	CcSEcCtD
Deferoxamine—Eosinophilia—Methotrexate—bone cancer	0.000302	0.00378	CcSEcCtD
Deferoxamine—Hypotension—Cisplatin—bone cancer	0.000295	0.0037	CcSEcCtD
Deferoxamine—Abdominal discomfort—Methotrexate—bone cancer	0.000292	0.00366	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000288	0.00361	CcSEcCtD
Deferoxamine—Blood creatinine increased—Doxorubicin—bone cancer	0.000286	0.00359	CcSEcCtD
Deferoxamine—Asthma—Epirubicin—bone cancer	0.000286	0.00358	CcSEcCtD
Deferoxamine—Dysuria—Methotrexate—bone cancer	0.000285	0.00357	CcSEcCtD
Deferoxamine—Paraesthesia—Cisplatin—bone cancer	0.000284	0.00356	CcSEcCtD
Deferoxamine—Eosinophilia—Epirubicin—bone cancer	0.000283	0.00354	CcSEcCtD
Deferoxamine—Dyspnoea—Cisplatin—bone cancer	0.000282	0.00353	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Cisplatin—bone cancer	0.000273	0.00342	CcSEcCtD
Deferoxamine—Infestation NOS—Methotrexate—bone cancer	0.000272	0.00341	CcSEcCtD
Deferoxamine—Infestation—Methotrexate—bone cancer	0.000272	0.00341	CcSEcCtD
Deferoxamine—Pain—Cisplatin—bone cancer	0.00027	0.00339	CcSEcCtD
Deferoxamine—Renal failure—Methotrexate—bone cancer	0.000267	0.00335	CcSEcCtD
Deferoxamine—Dysuria—Epirubicin—bone cancer	0.000267	0.00334	CcSEcCtD
Deferoxamine—Asthma—Doxorubicin—bone cancer	0.000264	0.00331	CcSEcCtD
Deferoxamine—Eosinophilia—Doxorubicin—bone cancer	0.000262	0.00328	CcSEcCtD
Deferoxamine—Infestation—Epirubicin—bone cancer	0.000255	0.00319	CcSEcCtD
Deferoxamine—Infestation NOS—Epirubicin—bone cancer	0.000255	0.00319	CcSEcCtD
Deferoxamine—Renal failure—Epirubicin—bone cancer	0.00025	0.00313	CcSEcCtD
Deferoxamine—Body temperature increased—Cisplatin—bone cancer	0.00025	0.00313	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Epirubicin—bone cancer	0.00025	0.00313	CcSEcCtD
Deferoxamine—Dysuria—Doxorubicin—bone cancer	0.000247	0.00309	CcSEcCtD
Deferoxamine—Urinary tract disorder—Methotrexate—bone cancer	0.000241	0.00302	CcSEcCtD
Deferoxamine—Urethral disorder—Methotrexate—bone cancer	0.000239	0.003	CcSEcCtD
Deferoxamine—Infestation NOS—Doxorubicin—bone cancer	0.000236	0.00295	CcSEcCtD
Deferoxamine—Infestation—Doxorubicin—bone cancer	0.000236	0.00295	CcSEcCtD
Deferoxamine—Visual impairment—Methotrexate—bone cancer	0.000235	0.00295	CcSEcCtD
Deferoxamine—Hypersensitivity—Cisplatin—bone cancer	0.000233	0.00292	CcSEcCtD
Deferoxamine—Bradycardia—Epirubicin—bone cancer	0.000233	0.00291	CcSEcCtD
Deferoxamine—Renal failure—Doxorubicin—bone cancer	0.000232	0.0029	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Doxorubicin—bone cancer	0.000231	0.00289	CcSEcCtD
Deferoxamine—Eye disorder—Methotrexate—bone cancer	0.000228	0.00286	CcSEcCtD
Deferoxamine—Tinnitus—Methotrexate—bone cancer	0.000228	0.00285	CcSEcCtD
Deferoxamine—Urinary tract disorder—Epirubicin—bone cancer	0.000226	0.00283	CcSEcCtD
Deferoxamine—Connective tissue disorder—Epirubicin—bone cancer	0.000225	0.00281	CcSEcCtD
Deferoxamine—Urethral disorder—Epirubicin—bone cancer	0.000224	0.00281	CcSEcCtD
Deferoxamine—Angiopathy—Methotrexate—bone cancer	0.000222	0.00278	CcSEcCtD
Deferoxamine—Immune system disorder—Methotrexate—bone cancer	0.000221	0.00276	CcSEcCtD
Deferoxamine—Visual impairment—Epirubicin—bone cancer	0.00022	0.00276	CcSEcCtD
Deferoxamine—Mediastinal disorder—Methotrexate—bone cancer	0.00022	0.00276	CcSEcCtD
Deferoxamine—Diarrhoea—Cisplatin—bone cancer	0.000216	0.00271	CcSEcCtD
Deferoxamine—Bradycardia—Doxorubicin—bone cancer	0.000215	0.0027	CcSEcCtD
Deferoxamine—Eye disorder—Epirubicin—bone cancer	0.000214	0.00268	CcSEcCtD
Deferoxamine—Tinnitus—Epirubicin—bone cancer	0.000213	0.00267	CcSEcCtD
Deferoxamine—Erythema—Methotrexate—bone cancer	0.000213	0.00266	CcSEcCtD
Deferoxamine—Urinary tract disorder—Doxorubicin—bone cancer	0.000209	0.00262	CcSEcCtD
Deferoxamine—Connective tissue disorder—Doxorubicin—bone cancer	0.000208	0.0026	CcSEcCtD
Deferoxamine—Angiopathy—Epirubicin—bone cancer	0.000207	0.0026	CcSEcCtD
Deferoxamine—Urethral disorder—Doxorubicin—bone cancer	0.000207	0.0026	CcSEcCtD
Deferoxamine—Immune system disorder—Epirubicin—bone cancer	0.000206	0.00259	CcSEcCtD
Deferoxamine—Mediastinal disorder—Epirubicin—bone cancer	0.000206	0.00258	CcSEcCtD
Deferoxamine—Arrhythmia—Epirubicin—bone cancer	0.000204	0.00256	CcSEcCtD
Deferoxamine—Visual impairment—Doxorubicin—bone cancer	0.000204	0.00255	CcSEcCtD
Deferoxamine—Vomiting—Cisplatin—bone cancer	0.000201	0.00252	CcSEcCtD
Deferoxamine—Vision blurred—Methotrexate—bone cancer	0.0002	0.00251	CcSEcCtD
Deferoxamine—Erythema—Epirubicin—bone cancer	0.000199	0.00249	CcSEcCtD
Deferoxamine—Eye disorder—Doxorubicin—bone cancer	0.000198	0.00248	CcSEcCtD
Deferoxamine—Tinnitus—Doxorubicin—bone cancer	0.000197	0.00247	CcSEcCtD
Deferoxamine—Angiopathy—Doxorubicin—bone cancer	0.000192	0.0024	CcSEcCtD
Deferoxamine—Muscle spasms—Epirubicin—bone cancer	0.000191	0.0024	CcSEcCtD
Deferoxamine—Immune system disorder—Doxorubicin—bone cancer	0.000191	0.00239	CcSEcCtD
Deferoxamine—Mediastinal disorder—Doxorubicin—bone cancer	0.000191	0.00239	CcSEcCtD
Deferoxamine—Leukopenia—Methotrexate—bone cancer	0.00019	0.00238	CcSEcCtD
Deferoxamine—Arrhythmia—Doxorubicin—bone cancer	0.000189	0.00237	CcSEcCtD
Deferoxamine—Nausea—Cisplatin—bone cancer	0.000188	0.00235	CcSEcCtD
Deferoxamine—Vision blurred—Epirubicin—bone cancer	0.000187	0.00235	CcSEcCtD
Deferoxamine—Convulsion—Methotrexate—bone cancer	0.000184	0.00231	CcSEcCtD
Deferoxamine—Erythema—Doxorubicin—bone cancer	0.000184	0.00231	CcSEcCtD
Deferoxamine—Arthralgia—Methotrexate—bone cancer	0.000181	0.00227	CcSEcCtD
Deferoxamine—Myalgia—Methotrexate—bone cancer	0.000181	0.00227	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.00018	0.00225	CcSEcCtD
Deferoxamine—Leukopenia—Epirubicin—bone cancer	0.000178	0.00223	CcSEcCtD
Deferoxamine—Muscle spasms—Doxorubicin—bone cancer	0.000177	0.00222	CcSEcCtD
Deferoxamine—Anaphylactic shock—Methotrexate—bone cancer	0.000173	0.00217	CcSEcCtD
Deferoxamine—Vision blurred—Doxorubicin—bone cancer	0.000173	0.00217	CcSEcCtD
Deferoxamine—Convulsion—Epirubicin—bone cancer	0.000172	0.00216	CcSEcCtD
Deferoxamine—Infection—Methotrexate—bone cancer	0.000172	0.00216	CcSEcCtD
Deferoxamine—Nervous system disorder—Methotrexate—bone cancer	0.00017	0.00213	CcSEcCtD
Deferoxamine—Thrombocytopenia—Methotrexate—bone cancer	0.00017	0.00213	CcSEcCtD
Deferoxamine—Arthralgia—Epirubicin—bone cancer	0.000169	0.00212	CcSEcCtD
Deferoxamine—Myalgia—Epirubicin—bone cancer	0.000169	0.00212	CcSEcCtD
Deferoxamine—Skin disorder—Methotrexate—bone cancer	0.000169	0.00211	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000168	0.00211	CcSEcCtD
Deferoxamine—Leukopenia—Doxorubicin—bone cancer	0.000165	0.00206	CcSEcCtD
Deferoxamine—Oedema—Epirubicin—bone cancer	0.000162	0.00203	CcSEcCtD
Deferoxamine—Anaphylactic shock—Epirubicin—bone cancer	0.000162	0.00203	CcSEcCtD
Deferoxamine—Hypotension—Methotrexate—bone cancer	0.000162	0.00203	CcSEcCtD
Deferoxamine—Infection—Epirubicin—bone cancer	0.000161	0.00202	CcSEcCtD
Deferoxamine—Shock—Epirubicin—bone cancer	0.00016	0.002	CcSEcCtD
Deferoxamine—Convulsion—Doxorubicin—bone cancer	0.000159	0.002	CcSEcCtD
Deferoxamine—Nervous system disorder—Epirubicin—bone cancer	0.000159	0.00199	CcSEcCtD
Deferoxamine—Thrombocytopenia—Epirubicin—bone cancer	0.000159	0.00199	CcSEcCtD
Deferoxamine—Tachycardia—Epirubicin—bone cancer	0.000158	0.00198	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000158	0.00198	CcSEcCtD
Deferoxamine—Skin disorder—Epirubicin—bone cancer	0.000158	0.00198	CcSEcCtD
Deferoxamine—Arthralgia—Doxorubicin—bone cancer	0.000157	0.00196	CcSEcCtD
Deferoxamine—Myalgia—Doxorubicin—bone cancer	0.000157	0.00196	CcSEcCtD
Deferoxamine—Paraesthesia—Methotrexate—bone cancer	0.000156	0.00195	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000156	0.00195	CcSEcCtD
Deferoxamine—Dyspnoea—Methotrexate—bone cancer	0.000155	0.00194	CcSEcCtD
Deferoxamine—Hypotension—Epirubicin—bone cancer	0.000152	0.0019	CcSEcCtD
Deferoxamine—Oedema—Doxorubicin—bone cancer	0.00015	0.00188	CcSEcCtD
Deferoxamine—Anaphylactic shock—Doxorubicin—bone cancer	0.00015	0.00188	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Methotrexate—bone cancer	0.00015	0.00188	CcSEcCtD
Deferoxamine—Infection—Doxorubicin—bone cancer	0.000149	0.00187	CcSEcCtD
Deferoxamine—Pain—Methotrexate—bone cancer	0.000148	0.00186	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000148	0.00185	CcSEcCtD
Deferoxamine—Shock—Doxorubicin—bone cancer	0.000148	0.00185	CcSEcCtD
Deferoxamine—Nervous system disorder—Doxorubicin—bone cancer	0.000147	0.00185	CcSEcCtD
Deferoxamine—Thrombocytopenia—Doxorubicin—bone cancer	0.000147	0.00184	CcSEcCtD
Deferoxamine—Tachycardia—Doxorubicin—bone cancer	0.000147	0.00184	CcSEcCtD
Deferoxamine—Skin disorder—Doxorubicin—bone cancer	0.000146	0.00183	CcSEcCtD
Deferoxamine—Paraesthesia—Epirubicin—bone cancer	0.000146	0.00183	CcSEcCtD
Deferoxamine—Dyspnoea—Epirubicin—bone cancer	0.000145	0.00181	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Methotrexate—bone cancer	0.000142	0.00178	CcSEcCtD
Deferoxamine—Hypotension—Doxorubicin—bone cancer	0.00014	0.00176	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Epirubicin—bone cancer	0.00014	0.00176	CcSEcCtD
Deferoxamine—Pain—Epirubicin—bone cancer	0.000139	0.00174	CcSEcCtD
Deferoxamine—Urticaria—Methotrexate—bone cancer	0.000138	0.00173	CcSEcCtD
Deferoxamine—Abdominal pain—Methotrexate—bone cancer	0.000137	0.00172	CcSEcCtD
Deferoxamine—Body temperature increased—Methotrexate—bone cancer	0.000137	0.00172	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000137	0.00171	CcSEcCtD
Deferoxamine—Paraesthesia—Doxorubicin—bone cancer	0.000135	0.00169	CcSEcCtD
Deferoxamine—Dyspnoea—Doxorubicin—bone cancer	0.000134	0.00168	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Epirubicin—bone cancer	0.000133	0.00166	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Doxorubicin—bone cancer	0.00013	0.00162	CcSEcCtD
Deferoxamine—Urticaria—Epirubicin—bone cancer	0.000129	0.00162	CcSEcCtD
Deferoxamine—Pain—Doxorubicin—bone cancer	0.000128	0.00161	CcSEcCtD
Deferoxamine—Abdominal pain—Epirubicin—bone cancer	0.000128	0.00161	CcSEcCtD
Deferoxamine—Body temperature increased—Epirubicin—bone cancer	0.000128	0.00161	CcSEcCtD
Deferoxamine—Hypersensitivity—Methotrexate—bone cancer	0.000128	0.0016	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Doxorubicin—bone cancer	0.000123	0.00154	CcSEcCtD
Deferoxamine—Pruritus—Methotrexate—bone cancer	0.000123	0.00154	CcSEcCtD
Deferoxamine—Hypersensitivity—Epirubicin—bone cancer	0.00012	0.0015	CcSEcCtD
Deferoxamine—Urticaria—Doxorubicin—bone cancer	0.000119	0.00149	CcSEcCtD
Deferoxamine—Body temperature increased—Doxorubicin—bone cancer	0.000119	0.00149	CcSEcCtD
Deferoxamine—Abdominal pain—Doxorubicin—bone cancer	0.000119	0.00149	CcSEcCtD
Deferoxamine—Diarrhoea—Methotrexate—bone cancer	0.000119	0.00149	CcSEcCtD
Deferoxamine—Pruritus—Epirubicin—bone cancer	0.000115	0.00144	CcSEcCtD
Deferoxamine—Dizziness—Methotrexate—bone cancer	0.000115	0.00144	CcSEcCtD
Deferoxamine—Diarrhoea—Epirubicin—bone cancer	0.000111	0.00139	CcSEcCtD
Deferoxamine—Hypersensitivity—Doxorubicin—bone cancer	0.000111	0.00139	CcSEcCtD
Deferoxamine—Vomiting—Methotrexate—bone cancer	0.00011	0.00138	CcSEcCtD
Deferoxamine—Headache—Methotrexate—bone cancer	0.000109	0.00136	CcSEcCtD
Deferoxamine—Dizziness—Epirubicin—bone cancer	0.000107	0.00134	CcSEcCtD
Deferoxamine—Pruritus—Doxorubicin—bone cancer	0.000106	0.00133	CcSEcCtD
Deferoxamine—Vomiting—Epirubicin—bone cancer	0.000103	0.00129	CcSEcCtD
Deferoxamine—Nausea—Methotrexate—bone cancer	0.000103	0.00129	CcSEcCtD
Deferoxamine—Diarrhoea—Doxorubicin—bone cancer	0.000103	0.00129	CcSEcCtD
Deferoxamine—Headache—Epirubicin—bone cancer	0.000102	0.00127	CcSEcCtD
Deferoxamine—Dizziness—Doxorubicin—bone cancer	9.93e-05	0.00124	CcSEcCtD
Deferoxamine—Nausea—Epirubicin—bone cancer	9.64e-05	0.00121	CcSEcCtD
Deferoxamine—Vomiting—Doxorubicin—bone cancer	9.55e-05	0.0012	CcSEcCtD
Deferoxamine—Headache—Doxorubicin—bone cancer	9.41e-05	0.00118	CcSEcCtD
Deferoxamine—Nausea—Doxorubicin—bone cancer	8.92e-05	0.00112	CcSEcCtD
